Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

VENTOLIN HFA 100 MCG

SALBUTAMOL (SALBUTAMOL SULFATE) : 100 MCG · DIN 02241497 · GLAXOSMITHKLINE INC

Health Canada status: MARKETED

VENTOLIN HFA 100 MCG METERED-DOSE AEROSOL - DIN 02241497
VENTOLIN HFA — DIN 02241497. Product photograph held by Nexara Health.

What is VENTOLIN HFA?

VENTOLIN HFA 100 MCG contains SALBUTAMOL (SALBUTAMOL SULFATE) : 100 MCG. It is listed in the Health Canada Drug Product Database under DIN 02241497, held by GLAXOSMITHKLINE INC, supplied as METERED-DOSE AEROSOL for INHALATION administration. Health Canada currently lists it as marketed, status dated 22-Nov-2001. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is VENTOLIN HFA used for?

VENTOLIN HFA (salbutamol pressurised inhalation, suspension) is indicated for: • the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor. • the prevention of exercise-induced bronchospasm.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02241497
Brand nameVENTOLIN HFA
Generic / active ingredientSALBUTAMOL (SALBUTAMOL SULFATE) : 100 MCG
ManufacturerGLAXOSMITHKLINE INC
Strength100 MCG
Dosage formMETERED-DOSE AEROSOL
Route of administrationINHALATION
SchedulePrescription
ATC codeR03AC02 SALBUTAMOL
AHFS class12:12.08.12
BiosimilarNo
Health Canada statusMARKETED
Status date22-Nov-2001
Original market date2001-11-22 00:00:00

How is it administered?

The dosage should be individualised, and the patient's response should be monitored by the prescribing physician on an ongoing basis. Adults and Adolescents (≥ 12 years): Relief of Acute Episodes of Bronchospasm: One to two puffs [100 to 200 mcg salbutamol] as needed. Prevention of Bronchospasm: One to two puffs [100 to 200 mcg salbutamol] every 4 to 6 hours, as needed, to a maximum of four times per day. Prevention of Exercise-induced Bronchospasm: Two puffs [200 mcg salbutamol] 15 minutes before exercise. Maximum Daily Dose: Eight puffs [800 mcg salbutamol]. Children (4 to < 12 years): Relief of Acute Episodes of Bronchospasm: One puff [100 mcg salbutamol] as needed. May be increased to two puffs (200 mcg salbutamol), if required. Prevention of Bronchospasm: One puff [100 mcg salbutamol] every 4 to 6 hours, as needed, to a maximum of four times per day. Prevention of Exercise-induced Bronchospasm: One puff [100 mcg salbutamol] 15 minutes before exercise. May be increased to two puffs (200 mcg salbutamol), if required. Maximum Daily Dose: Four puffs [400 mcg salbutamol]. VENTOLIN HFA is administered by the inhaled route only. To ensure administration of the proper dose of the drug, the patient should be instructed by the physician or other healthcare professional on the proper use of the pressurised inhalation, suspension. Inhaler actuation should be synchronised with inspiration to ensure optimum delivery of drug to the lungs. In patients who find coordination of a pressurised metered dose inhaler difficult, a spacer may be used with VENTOLIN HFA. Priming: It is recommended to test spray VENTOLIN HFA into the air four times, away from the face, before using for the first time and in cases where the aerosol has not been used for more than 5 days. The inhaler contains enough salbutamol for 200 actuations (puffs) only. After 200 actuations (puffs), the inhaler can continue to spray but without the prescribed dose of salbutamol. Maintaining a record of the number of actuations (puffs) administered to the patient should be considered, towards avoiding inadvertent use of an empty inhaler. Keeping a back-up inhaler could be considered.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Replace the mouthpiece cover firmly and snap it into position. Keep out of the sight and reach of children. Store at a temperature between 15°C and 25°C. The contents of VENTOLIN HFA are under pressure. The container may explode if heated. Do not place in hot water or near radiators, stoves or other sources of heat. Even when empty, do not puncture or incinerate container. As with most inhaled medications in aerosol canisters, the therapeutic effect of this medication may decrease when the canister is cold.

How is it supplied?

VENTOLIN HFA is available in 200 dose formats. VENTOLIN HFA is a pressurized metered dose inhaler (MDI) consisting of an aluminum canister fitted with a metering valve. Each canister is fitted into the supplied blue plastic actuator. A blue dust cap is fitted over the actuator's mouthpiece when not in use. Each depression of the valve delivers 100 mcg of salbutamol (as sulfate).

Contraindications

Patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. As a tocolytic in patients at risk of premature labour or threatened abortion.

Warnings and precautions

Patients should always carry their VENTOLIN HFA to use immediately if an episode of asthma is experienced. If therapy does not produce a significant improvement or if the patient's condition worsens, medical advice must be sought to determine a new plan of treatment. In the case of acute or rapidly worsening dyspnea, a physician should be consulted immediately. Cardiovascular: In individual patients, any beta2-adrenergic agonist, including salbutamol, may have a clinically significant cardiac effect. Care should be taken with patients suffering from cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias and hypertension. Special care and supervision are required in patients with idiopathic hypertrophic subvalvular aortic stenosis, in whom an increase in the pressure gradient between the left ventricle and the aorta may occur, causing increased strain on the left ventricle. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. The exact cause of death is unknown, but cardiac arrest following an unexpected development of a severe acute asthmatic crisis and subsequent hypoxia is suspected. Endocrine and Metabolism: Metabolic Effects: Salbutamol sulfate can induce reversible metabolic changes such as potentially serious hypokalemia, particularly following nebulised or especially infused administration. Particular caution is advised in acute severe asthma since hypokalemia may be potentiated by concomitant treatment with xanthine derivatives, steroids and diuretics and by hypoxia. Hypokalemia will increase the susceptibility of digitalis-treated patients to cardiac arrhythmias. It is recommended that serum potassium levels be monitored in such situations. Care should be taken with patients with diabetes mellitus. Salbutamol can induce reversible hyperglycemia during nebulised administration or especially during infusions of the drug. The diabetic patient may be unable to compensate for this and the development of ketoacidosis has been reported. Concurrent administration of corticosteroids can exaggerate this effect. Care should be taken with patients with hyperthyroidism. Immune: Hypersensitivity: Immediate hypersensitivity reactions may occur after administration of salbutamol sulfate, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, hypotension, anaphylaxis and oropharyngeal edema. Care should be taken in patients who are unusually responsive to sympathomimetic amines. Neurologic: Care should be taken with patients with convulsive disorders. Respiratory: As with other inhaled medications, paradoxical bronchospasm may occur characterized by an immediate increase in wheezing after dosing. This should be treated immediately with an alternative presentation or a different fast-acting inhaled bronchodilator to relieve acute asthmatic symptoms. VENTOLIN HFA should be discontinued immediately, the patient assessed and if necessary, alternative therapy instituted. Overuse of short-acting beta-agonists may mask the progression of the underlying disease and contribute to deteriorating asthma control, leading to an increased risk of severe asthma exacerbations and mortality.

Is SALBUTAMOL in shortage in Canada?

A Canadian shortage report is on file for this molecule: Resolved — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.

Check availability for VENTOLIN HFA

What can be used instead?

Other Canadian products sharing ATC code R03AC02 SALBUTAMOL. 11 of 63 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
APO-SALBUTAMOL HFA100 MCGMETERED-DOSE AEROSOLAPOTEX INCMARKETEDDIN 02245669
PMS-SALBUTAMOL0.5 MGSOLUTIONPHARMASCIENCE INCMARKETEDDIN 02208245
PMS-SALBUTAMOL1 MGSOLUTIONPHARMASCIENCE INCMARKETEDDIN 02208229
PMS-SALBUTAMOL2 MGSOLUTIONPHARMASCIENCE INCMARKETEDDIN 02208237
SALBUTAMOL HFA100 MCGMETERED-DOSE AEROSOLSANIS HEALTH INCMARKETEDDIN 02419858
TEVA-SALBUTAMOL HFA100 MCGMETERED-DOSE AEROSOLTEVA CANADA LIMITEDMARKETEDDIN 02326450
TEVA-SALBUTAMOL STERINEBS P.F.1 MGSOLUTIONTEVA CANADA LIMITEDMARKETEDDIN 01926934
TEVA-SALBUTAMOL STERINEBS P.F.2 MGSOLUTIONTEVA CANADA LIMITEDMARKETEDDIN 02173360
VENTOLIN DISKUS200 MCGPOWDERGLAXOSMITHKLINE INCMARKETEDDIN 02243115
VENTOLIN RESPIRATOR SOLUTION5 MGSOLUTIONGLAXOSMITHKLINE INCMARKETEDDIN 02213486

Who else supplies SALBUTAMOL worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. SALBUTAMOL appears in 2807 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for VENTOLIN HFA

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for VENTOLIN HFA

Health Canada Drug Product Database (DPD), DIN 02241497. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.